Literature DB >> 7857625

Experimental, clinical and preventive aspects of ototoxicity.

A A Chiodo1, P W Alberti.   

Abstract

Ototoxicity is an important clinical problem and accounts for a significant proportion of sensorineural hearing loss in some parts of the world. Ototoxicity is predominantly an iatrogenic condition. However, with proper dosing, prudent monitoring of serum levels of ototoxic medications and serial audiometry, ototoxicity can be prevented. A number of the more common ototoxic medications, including aminoglycosides, erythromycin, loop diuretics, salicylates, cisplatin, deferoxamine and ototopical agents, are outlined in this review. Their pharmacology, mechanisms of action and methods of preventing complications are discussed together with animal and clinical studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7857625     DOI: 10.1007/bf00181963

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  206 in total

1.  Ototoxicity of neomycin and polymyxin B following middle ear application in the chinchilla and baboon.

Authors:  C G Wright; W L Meyerhoff; A R Halama
Journal:  Am J Otol       Date:  1987-11

2.  Clinical perspectives on ototoxic drugs.

Authors:  G J Matz
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1990-06

3.  Salicylate ototoxicity; a clinical and experimental study.

Authors:  E N Myers; J M Bernstein
Journal:  Arch Otolaryngol       Date:  1965-11

4.  Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia.

Authors:  R H Mathog; W J Klein
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

5.  Ototoxicity of erythromycin in peritoneal dialysis patients.

Authors:  R Taylor; I S Schofield; J M Ramos; A J Bint; M K Ward
Journal:  Lancet       Date:  1981-10-24       Impact factor: 79.321

6.  High-dose cisplatin treatment: hearing loss and plasma concentrations.

Authors:  G Laurell; U Jungnelius
Journal:  Laryngoscope       Date:  1990-07       Impact factor: 3.325

7.  Erythromycin ototoxicity: analysis and conclusions based on 22 case reports.

Authors:  R C Haydon; J W Thelin; W E Davis
Journal:  Otolaryngol Head Neck Surg       Date:  1984-12       Impact factor: 3.497

8.  Characteristics and drug responses of cochlear and vestibular adenylate cyclase.

Authors:  D Bagger-Sjöbäck; C S Filipek; J Schacht
Journal:  Arch Otorhinolaryngol       Date:  1980

9.  Ototoxicity of cis-platinum and its relationship to eye colour.

Authors:  R M Barr-Hamilton; L M Matheson; D G Keay
Journal:  J Laryngol Otol       Date:  1991-01       Impact factor: 1.469

10.  An experimental study using sodium salicylate to reduce cochlear changes induced by furosemide.

Authors:  L P Rybak; W Santiago; C Whitworth
Journal:  Arch Otorhinolaryngol       Date:  1986
View more
  9 in total

1.  Cochlear microphonic potential recorded by transtympanic electrocochleography in normally-hearing and hearing-impaired ears.

Authors:  R Santarelli; P Scimemi; E Dal Monte; E Arslan
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-04       Impact factor: 2.124

2.  Interaction of tamoxifen and noise-induced damage to the cochlea.

Authors:  Jagan A Pillai; Jonathan H Siegel
Journal:  Hear Res       Date:  2011-09-02       Impact factor: 3.208

3.  An increasing prevalence of hearing impairment and associated risk factors over three decades of the Alameda County Study.

Authors:  M I Wallhagen; W J Strawbridge; R D Cohen; G A Kaplan
Journal:  Am J Public Health       Date:  1997-03       Impact factor: 9.308

4.  The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.

Authors:  Angela C Garinis; Campbell P Cross; Priya Srikanth; Kelly Carroll; M Patrick Feeney; Douglas H Keefe; Lisa L Hunter; Daniel B Putterman; David M Cohen; Jeffrey A Gold; Peter S Steyger
Journal:  J Cyst Fibros       Date:  2017-02-24       Impact factor: 5.482

5.  Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure.

Authors:  Campbell P Cross; Selena Liao; Zachary D Urdang; Priya Srikanth; Angela C Garinis; Peter S Steyger
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2015-09-09       Impact factor: 1.675

6.  Susceptibility of microorganisms isolated from chronic suppurative otitis media to ciprofloxacin.

Authors:  A Altuntas; A Aslan; N Eren; A Unal; Y Nalca
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

7.  Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.

Authors:  Abolhassan Faramarzi; Mehran Karimi; Seyed-Taghi Heydari; Mahmoud Shishegar; Masoud Kaviani
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

8.  New Advances in Evaluation of Hearing in a Sample of Egyptian Children with β-Thalassemia Major.

Authors:  Fatma A Alzaree; Manal A Shehata; Mohamed Abdel Atti; Gihan A Elzaree; Ghada M El-Kassas
Journal:  Open Access Maced J Med Sci       Date:  2019-05-15

9.  Protective Effects of Deferoxamine on Vestibulotoxicity in Gentamicin-Induced Bilateral Vestibulopathy Rat Model.

Authors:  Hyo-Jung Kim; Jin-Ok Lee; Ji-Soo Kim
Journal:  Front Neurol       Date:  2021-03-24       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.